Gregg Fergus

Gregg Fergus is currently on the Board of Directors at Neuvivo, AIQ Solutions and Verda Bio. In the non-profit world, Gregg is on the Board of Visitors at the Wisconsin Institutes of Discovery and has been a Strategic Advisor to Healthy Minds Innovations focusing on both the environment and mental health.

Gregg has experience in all aspects of life sciences including, genomics, proteomics, pharmaceutics, med tech, diagnostics and agriculture. He has founded or sat on the board of numerous companies including: Cernostics (bought by Castle Biosciences in 2021), PFS Genomics (bought by Exact Sciences in 2021), Celsee (bought by Biorad in 2020) and Igenomix (bought by Twist Biosciences in 2020).

From 2014-2020, Gregg was Chief Executive Officer and Chief Commercial Officer of 4Catalyzer, a Guilford, Connecticut-based startup accelerator dedicated to democratizing healthcare and maximizing societal impact. 4Catalyzer was the brainchild of Jonathan Rothberg and Gregg Fergus. Together, they co-founded, funded, and supported four companies and raised more than $800 million in capital. Butterfly Network, QSi and Hyperfine all went public in 2021.

Prior to joining 4Catalyzer, Gregg was the President and Chief Operating Officer of Ion Torrent, which pioneered an entirely new approach to DNA sequencing and sold to Life technology for $725M pre-revenue. Gregg’s previous executive roles include Executive in Residence at RW Baird/Baird Venture Partners, where he provided investment thesis, deal-flow, and industry contacts for the life science tools market; Chief Commercial Officer of Cellular Dynamics International; and Senior Vice President of Sales and Global Operations at Affymetrix, Inc. Gregg is an alumnus of UW-Madison with a degree in Bacteriology.